Freeline Therapeutics (FRLN) Stock Price, News & Analysis

Company Overview

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key Stats

• Today's Range: $6.48 to $6.48
• 50-Day Range: $6.43 to $6.49
• 52-Week Range: $2.11 to $8.74
• Volume: N/A
• Average Volume: 12,055 shs
• Market Capitalization: $28.12 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FRLN Stock Analysis - Frequently Asked Questions

How were Freeline Therapeutics' earnings last quarter?

Freeline Therapeutics Holdings plc (NASDAQ:FRLN) announced its earnings results on Tuesday, November, 9th. The company reported ($12.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($15.20) by $2.30.

When did Freeline Therapeutics' stock split?

Shares of Freeline Therapeutics reverse split before market open on Friday, May 12th 2023. The 1-15 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Freeline Therapeutics IPO?

Freeline Therapeutics (FRLN) raised $126 million in an initial public offering on Friday, August 7th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. J.P. Morgan, Morgan Stanley and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

What other stocks do shareholders of Freeline Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Freeline Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Jabil (JBL), Adobe (ADBE), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 5/24/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FRLN
• CIK: 1810031
• Web: www.freeline.life
• Phone: 44-0-14-3890-6870
• Fax: N/A
• Employees: 152
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($5.5939)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-88,970,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -150.46%
• Return on Assets: -97.01%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.95
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $12.07 per share
• Price / Book: 0.54

Miscellaneous

• Outstanding Shares: 4,340,000
• Free Float: 4,259,000
• Market Cap: $28.12 million
• Optionable: Not Optionable
• Beta: 0.66